news
Blood epigenomic test could subtype lung cancer without biopsy
Researchers at Stanford Medicine developed a new blood-based epigenomic test that can identify molecular features of small-cell lung cancer, typically requiring a tissue biopsy. This non-invasive method could help doctors track tumor changes and subtypes over time, potentially allowing for more dynamic treatment adjustments.
Researchers at Stanford Medicine developed a new blood-based epigenomic test that can identify molecular features of small-cell lung cancer, typically requiring a tissue biopsy. This non-invasive method could help doctors track tumor changes and subtypes over time, potentially allowing for more dynamic treatment adjustments.
The architecture take
The body's signals are everywhere if you know how to read them. This isn't about general cancer screening, but specifically about getting a clearer picture of an existing cancer's biology from a simple blood draw. Biopsies are invasive and painful, and they're just a snapshot — a single moment in time. Cancer isn't static; it evolves, and treatment needs to keep up. Being able to pull precise epigenomic data from plasma means doctors could check in on the tumor's state far more frequently, tweaking therapies based on real-time molecular changes. I see this as a step towards making precision medicine less of a one-and-done and more of a continuous feedback loop. It's about reducing the physical load of diagnostics while increasing the information we get from the body.